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SUMMARY
Cells with distinct phenotypes including stem-cell-like properties have been proposed to exist in
normal human mammary epithelium and breast carcinomas, but their detailed molecular character-
istics and clinical significance are unclear. We determined gene expression and genetic profiles of
cells purified from cancerous and normal breast tissue using markers previously associated with
stem-cell-like properties. CD24+ and CD44+ cells from individual tumors were clonally related but
not always identical. CD44+ cell-specific genes included many known stem-cell markers and corre-
lated with decreased patient survival. The TGF-b pathway was specifically active in CD44+ cancer
cells, where its inhibition induced a more epithelial phenotype. Our data suggest prognostic
relevance of CD44+ cells and therapeutic targeting of distinct tumor cell populations.INTRODUCTION
Tumors originate from normal cells due to accumulated
genetic and epigenetic alterations, but the identity of the
tumor-initiating cells is largely unknown. Stem cells have
been proposed as attractive targets since they share
many characteristics with cancer cells, including thecapacity to self-renew, give rise to heterogeneous prog-
eny, and migrate and invade into surrounding tissue. Cor-
relating with this, several pathways and genes required for
normal stem-cell function are activated in cancer cells
and play essential roles in tumorigenesis (Weissman,
2005). Cancer stem cells have been defined as a subset
of tumor cells with stem-cell-like properties that areSIGNIFICANCE
Clonal evolution is a prevailing concept of cancer biology explaining the initiation and progression of solid tumors.
The cancer-stem-cell hypothesis is an alternative model that recently has received a lot of attention. Here, we
determined molecular profiles of distinct breast cancer cell populations purified using markers previously associ-
ated with stem-cell-like properties. Although we found that CD24+ and CD44+ cells are more differentiated and
progenitor-like, respectively, and that their gene expression differences may have prognostic relevance, our
finding of genetic differences between these cells within individual tumors supports a clonal evolution hypothesis
involving intratumoral heterogeneity.Cancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc. 259
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Breast Cancer ‘‘Stem Cells’’?thought to be responsible for the growth, progression, and
recurrence of a tumor (Clarke and Fuller, 2006; Lynch
et al., 2006; Polyak and Hahn, 2006; Weissman, 2005;
Wicha et al., 2006). This hypothesis was proposed many
years ago and revived in recent years with new experi-
mental approaches. Putative cancer stem cells have
been purified from various human tumor types, frequently
using cell surface markers specific for the normal stem
cells of the same organ (Clarke and Fuller, 2006; Lynch
et al., 2006; Polyak and Hahn, 2006; Weissman, 2005;
Wicha et al., 2006). The tumorigenicity and the ‘‘stemness’’
of these isolated cells have been demonstrated by per-
forming in vitro clonogenicity and in vivo tumorigenicity
studies.
The stages of human mammary epithelial cell differenti-
ation and markers uniquely identifying differentiated and
progenitor cells are not well defined. In vitro clonogenicity
studies suggest the existence of bipotential progenitors
that can give rise to both luminal epithelial and myoepithe-
lial cells, lineage-restricted luminal epithelial and myoepi-
thelial progenitors, and differentiated luminal epithelial
and myoepithelial cells (Bocker et al., 2002; Clarke et al.,
2005; Clayton et al., 2004; Dontu et al., 2003; Liu et al.,
2006; Lynch et al., 2006; Stingl et al., 1998, 2005). MUC1
and CD10 (CALLA/MME) are thought to be expressed
by luminal epithelial and myoepithelial cells, respectively
(Clayton et al., 2004; Stingl et al., 1998, 2005). CD44
is present in progenitor cells, yet which epithelial cells
express CD24 has not been determined in the normal
human breast. In breast cancer, Al-Hajj et al. demon-
strated that lin/CD44+/CD24/low (subsequently referred
to as CD44+) cells from malignant pleural effusions of
breast cancer patients were more tumorigenic in NOD/
SCID mice than CD44/CD24+ (subsequently referred to
as CD24+) cells, and the resulting xenografts reproduced
the heterogeneity of the original tumors, leading to the
hypothesis that CD44+ cells are breast cancer stem cells
(Al-Hajj et al., 2003). Subsequent studies in breast and
prostate cancer confirmed that CD44+ cells are tumori-
genic when injected into immunodeficient mice and have
progenitor-like properties (Patrawala et al., 2005; Ponti
et al., 2005). None of these studies have analyzed the
comprehensive molecular profiles and clinical relevance
of CD44+ and CD24+ cells or provided conclusive evi-
dence that CD44+ tumor cells are stem cells and CD24+
tumor cells are their progeny. Furthermore, the relation-
ship between the cancer-stem-cell and the genetic-
clonal-evolution hypotheses of tumor progression has
not been investigated.
To begin addressing these issues, we purified cells us-
ing CD44 and CD24 from breast carcinomas and deter-
mined their global gene expression and genetic profiles.
For comparison, we also isolated and characterized
CD44+ and CD24+ cells from normal human mammary
epithelium. Gene signatures specific for CD44+ breast
cancer cells were enriched for known stem-cell markers
and correlated with clinical outcome and activity of signal-
ing pathways, but cancer CD24+ and CD44+ cells were
not always genetically identical.260 Cancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc.RESULTS
Purification and Gene Expression Profiles of Distinct
Breast Epithelial Cell Populations
We purified distinct subpopulations of normal mammary
epithelial and breast cancer cells using cell surface
markers that have been described to be specifically
expressed in differentiated cells or in cells with stem-
cell-like properties (Al-Hajj et al., 2003; Dontu et al.,
2003; Stingl et al., 1998) (Figure 1A). We purified
CD24+ and CD44+ cells from normal human breast tis-
sue derived from reduction mammoplasty and from
breast tumors of different stages. Based on the initial
gene expression profiling of CD44+ cells from pleural
effusion and ascites samples, we identified a CD44+
cell-specific gene (PROCR) that encodes a cell surface
receptor and has expression more specific to CD44+ ep-
ithelial cells than CD44, which is also expressed in leuko-
cytes and myofibroblasts. PROCR has been identified as
a marker of hematopoietic, hair-follicle, neural, and
embryonic stem cells (Blanpain et al., 2004; Ivanova
et al., 2002; Ramalho-Santos et al., 2002). After confirm-
ing that 100% of CD44+ tumor cells are positive for
PROCR (data not shown), we used this marker to isolate
CD44+/PROCR+ (subsequently referred to as PROCR+)
cells from primary invasive breast tumors (see
Figure S1A in the Supplemental Data available with this
article online). A detailed description of the purification
procedure and the tissue samples is provided in the
Supplemental Data.
We confirmed the purity and differentiation status of the
cell fractions by semiquantitative RT-PCR using leuko-
cyte, luminal epithelial, myoepithelial, and stem-cell
markers (Dontu et al., 2003) (Figures 1B–1D and Fig-
ure S1B). The nearly mutually exclusive expression of
known luminal epithelial and stem-cell markers in the
CD24+ and CD44+ cells, respectively, suggested that
they might indeed represent luminal epithelial and pro-
genitor-like cells, respectively. The low abundance of
estrogen receptor a (ESR1) in the CD44+ cells both in
normal breast tissue and breast carcinomas implies that
these cells are not responsive to estrogenic hormones
(Figures 1B–1D and Table 1II). The lack of estrogen and
progesterone receptors and ERBB2 in normal CD44+
cells further supports that these cells may represent pro-
genitors since mouse mammary epithelial stem cells do
not express these proteins (Asselin-Labat et al., 2006).
We also analyzed the expression of genes associated
with self-renewal, including BMI1 and hedgehog (Hh)-
signaling pathway genes. Gli1 and Gli2 were more highly
expressed in CD44+ cells than in CD24+ cells, reflecting
activation of Hh signaling, while BMI1 expression was
essentially the same in both cell populations (Figures
S1C and S1D).
To determine the comprehensive gene expression
profiles of the purified cells, we generated SAGE (serial
analysis of gene expression) libraries from CD24+ and
CD44+ cells purified from normal mammary epithelium
and pleural effusion, ascites, and primary invasive tumor
Cancer Cell
Breast Cancer ‘‘Stem Cells’’?Figure 1. Purification and Gene Expression Analysis of Distinct Cell Subpopulations
(A) Schematic outline of purification of the various cells from normal breast tissue and invasive and metastatic breast carcinomas. Cells are captured
using the indicated antibody-coupled magnetic beads specific for each cell type. Purification steps marked with rectangles were not always included
in the procedure, while myofibroblasts, marked with an asterisk, were only present in invasive tumors. IDC, invasive ductal carcinoma. Semiquanti-
tative RT-PCR analysis of purified cell fractions isolated from normal breast tissue (N1) (B), pleural effusion (PE2) (C), and primary invasive ductal car-
cinoma (IDC28) (D). RNA from CD24+, CD44+, and PROCR+ cells was tested for the expression of known differentiated (Diff) and stem (Stem)-cell-
specific genes. CD44+ and PROCR+ cells lack differentiation markers and are positive for stem-cell markers. In the primary invasive tumor, the
CD44+ fraction is contaminated by leukocytes, as demonstrated by high levels of CD45 leukocyte common antigen (PTPRC) expression. ACTB
was used as loading control. Each triangle indicates an increasing number of PCR cycles (25, 30, 35). (E) Dendrogram depicting relatedness of
SAGE libraries prepared from CD44+, PROCR+, and CD24+ cells. Hierarchical clustering was applied to SAGE data for the indicated libraries,
and selected portions of the clustering heat map are shown here. Each row represents a tag and is labeled with the symbol of the gene that best
matches that tag (or ‘‘no match’’ if no matching transcript was found). Red and green indicate high and low expression levels, respectively. The ex-
pression profiles of normal and cancer CD44+ and PROCR+ cells are more similar to each other than to those of CD24+ cells derived from the same
tissues. ASC, ascites; PE, pleural effusion; N, normal; IDC, invasive ductal carcinoma. (F) Gene ontology biological process categories highly repre-
sented in pools of all SAGE libraries from different cell populations. Categories with an enrichment score >2 in at least one library pool using the DAVID
Functional Annotation Tool are plotted. Cell populations represented include cancer CD44+ and PROCR+ (red), normal CD44+ and PROCR+ (pink),
cancer CD24+ (dark blue), and normal CD24+ (light blue) cells.samples collected from breast cancer patients (details in
the Supplemental Data). We assigned each SAGE library
a name based on the sample and cell surface marker
used to purify the cells from which it was prepared.
The SAGE data further supported the hypothesis that
CD24+ and CD44+ cells represent more differentiated
luminal epithelial and progenitor-like cells, respectively,
since known markers of these cells were nearly mutually
exclusively found in the respective SAGE libraries (Tables
1I and 1II and Tables S1–S6). Unsupervised hierarchicalclustering of the SAGE libraries demonstrated that
normal and cancer CD44+ and PROCR+ cells are more
similar to each other than to CD24+ cells from the
same tissue (Figure 1E). Functional classification of the
genes expressed in the various SAGE libraries revealed
that cancer and normal CD44+ and PROCR+ cells are
more enriched for genes involved in cell motility, chemo-
taxis, hemostasis, and angiogenesis, while CD24+ cells
more highly express genes implicated in carbohydrate
metabolism and RNA splicing (Figure 1F).Cancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc. 261
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Breast Cancer ‘‘Stem Cells’’?Table 1. Selected Genes Differentially Expressed between CD44+ or PROCR+ and CD24+ Cells
Matching SAGE tag sequences, counts per 200,000 tags in each indicated SAGE library, and gene symbols and descriptions are
listed for genes encoding known stem (I) or differentiated (II) cell markers or TGF-b pathway components and targets (III). N, nor-
mal; PE, pleural effusion; ASC, ascites; IDC, invasive ductal carcinoma.Genetic Alterations in CD24+ and CD44+
Breast Cancer Cells
To determine the clonal relationship between CD24+ and
CD44+ cells within individual tumors, genomic DNA iso-
lated from these cells was analyzed on SNP arrays. The re-
sulting data demonstrated that in some tumors the two
cell fractions have the same copy-number alterations
and appear to be genetically identical (Figure 2A). To ana-
lyze the genetic composition of the CD24+ and CD44+
cells at the single-cell level, we developed a protocol for
their short-term in vitro culture that maintained their
phenotypes based on the analysis of cell surface and262 Cancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc.cell-type-specific markers (Figures 2B and 4C). These pri-
mary cultures were used for metaphase FISH analyses
using BAC probes corresponding to chromosomal areas
frequently amplified in breast cancer and containing
genes specifically and highly expressed in tumor CD24+
or CD44+ cells. This analysis identified a genetic alteration
that was common to all cell fractions (8q24.3 rearrange-
ment) as well as one only detected in CD24+ cells
(1q21.3 gain) (Figure 2C). This distinct genetic change
was detected in all CD24+ cells and was present in the
original tumor (Figure 2D). Thus, we determined that
CD44+ and CD24+ cells within individual tumors are
Cancer Cell
Breast Cancer ‘‘Stem Cells’’?Figure 2. Analysis of the Genetic Profiles of Distinct Tumor Cell Subpopulations
(A) SNP array analysis of copy-number changes relative to normal leukocytes from the same patient in CD24+, CD44+, and PROCR+ cells isolated
from pleural effusions (PE2 and PE6) and an invasive ductal carcinoma (IDC31). PROCR+* cells are PROCR+ cells further selected with CD44 anti-
bodies. Red and blue indicate copy-number gain and loss, respectively. The pairs of distinct cell populations from each tumor overall appear to have
identical copy number changes. Chr, chromosome.
(B) FACS analysis of primary cultured pleural effusion (pcPE) CD44+ and CD24+ cells using anti-CD24 and anti-CD44 antibodies conjugated with FITC
and PE, respectively. CD44 and CD24 are mutually exclusively expressed in the CD44+ and CD24+ cells.
(C) FISH analysis of metaphase chromosomes and interphase nuclei prepared from primary cultured pleural effusion (pcPE) CD24+, CD44+, and
PROCR+ cells using BAC RP11-157A11 mapped to 1q21.3 (green) and BAC CTD-2349A18 mapped to 8q24.3 (red). FISH with the 8q24.3-specific
probe revealed a hybridization pattern characteristic of rearrangement at this locus (two brighter, larger and two weaker, smaller signals) in all three
cell fractions. FISH with the 1q21.3-specific probe revealed multiple signals (four to seven) on metaphase chromosomes and interphase nuclei,
characteristic of a gain of chromosomal material from the long (q) arm of chromosome 1.
(D) FISH analysis of uncultured pleural effusion (PE) CD24+ cells using BAC RP11-157A11 mapped to 1q21.3 and a chromosome 1 centromeric (cen)
probe (D1Z5). Representative interphase nuclei are shown with multiple hybridization signals specific to the 1q21.3 locus (green) as well as three and
four hybridization signals specific to the centromeric region (red), consistent with a gain of chromosome 1 material.clonally related but that the CD24+ cells can have addi-
tional genetic changes not present in the CD44+ cells.
Signaling Pathways Active in CD44+ Cells
To identify signaling pathways based on our SAGE data
that are specifically activated in CD24+ or CD44+ cells,
we utilized the MetaCore data mining technology recentlyapplied for functional analysis of high-throughput data
(Ekins et al., 2006; Jarvinen et al., 2006; Lee et al., 2006;
Nikolsky et al., 2005a, 2005b; Soreghan et al., 2005). First,
we ranked gene ontology functional processes and ca-
nonical pathways according to how statistically signifi-
cantly they fit to the lists of genes most highly overrepre-
sented in normal or cancer CD44+ cell SAGE librariesCancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc. 263
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Breast Cancer ‘‘Stem Cells’’?Figure 3. Network of TGF-b Signaling
Pathway Upregulated in Cancer CD44+
Cells
Direct interaction network centered around
TGF-b for genes upregulated in cancer and
not normal CD44+ cells compared to corre-
sponding CD24+ cells. Colors of the lines indi-
cate inhibition (red), activation (green), and no
clear link (gray).compared to corresponding CD24+ cell SAGE libraries
(Figures S2A and S2B and data not shown). Among
gene ontology functional processes, cell motility, cell ad-
hesion, protein biosynthesis, protein folding, and cell pro-
liferation strongly fit genes upregulated in normal CD44+
cells and genes upregulated in cancer CD44+ cells. Cell
motility and cell adhesion had high dispersion scores in
this analysis, indicating that different sets of genes within
each process are upregulated in cancer and normal
CD44+ cells. Among canonical pathways, TGF-b and
WNT signaling, cytoskeleton remodeling, integrin-mediated
processes, reverse signaling by ephrin B, and chemokines
and cell adhesion strongly fit genes upregulated in normal
CD44+ cells and genes upregulated in cancer CD44+
cells. A map of the genes involved in TGF-b and WNT sig-
naling and cytoskeleton remodeling and a more detailed
view of the TGF-b pathway are depicted in Figures S3
and S4.
We also used the MetaCore data mining technology to
perform a more detailed analysis of which pathways are
differentially regulated in CD44+ and CD24+ cells by
building direct interaction (DI) networks around the lists
of genes most highly overrepresented in normal or cancer
CD44+ cell SAGE libraries compared to corresponding
CD24+ cell SAGE libraries. A DI network built around can-
cer CD44+ cell-specific genes is centered around TGF-b1
(Figure 3 and Figure S5). Modules around TGF-b1, dyna-
min, fibronectin, caveolin, and casein kinase II are upregu-
lated only in cancer CD44+ cells, while modules around
collagen 1 and transcription factors HIF1A and ETS1 are
upregulated in cancer and normal CD44+ cells (Figures
S6 and S7). DI networks built around normal CD44+
cell-specific genes are centered around VEGF-A, IL-1,
NF-kb, AP-1, Rac1, and SMAD3 and feature activation
of the Notch pathway and TGF-b3 (Figures S8, S10, and
S13). A subnetwork of the cancer CD44+ cell-specific
genes DI network centered around TGF-b1 containing
breast-cancer-relevant genes is shown in Figure S9, and264 Cancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc.additional networks built around genes upregulated in
CD44+ cells from individual cancer samples are shown
in Figures S11, S12, S14, and S15.
The TGF-b Pathway in Breast Cancer CD44+ Cells
Due to the known importance of TGF-b signaling in regu-
lating the pluripotency of human embryonic stem cells
(James et al., 2005); its roles in differentiation, tumorigen-
esis, and metastasis (Moses and Serra, 1996; Muraoka-
Cook et al., 2005; Roberts and Wakefield, 2003; Siegel
and Massague, 2003); and our SAGE (Table 1III) and
MetaCore data implicating this pathway in CD44+ cells,
we investigated its role in breast cancer CD44+ cells in fur-
ther detail. We analyzed the expression of selected genes
involved in TGF-b signaling by semiquantitative RT-PCR in
CD44+ and CD24+ cells (Figure 4A). Correlating with our
SAGE and MetaCore data, TGF-b1 was almost exclusively
expressed in tumor CD44+ cells together with TGFBR2,
one of the signaling receptors for TGF-b (Figure 4A). The
dramatic difference in TGFBR2 mRNA levels between
tumor CD24+ and CD44+ cells suggests potential under-
lying epigenetic regulation of this gene. Chromatin modifi-
cation and promoter methylation have been described as
potential mechanisms leading to silencing of TGFBR2 in
some tumors (Osada et al., 2005; Zhang et al., 2004;
Zhao et al., 2005). We analyzed the DNA methylation sta-
tus of TGFBR2 in tumor CD44+ and CD24+ cells and de-
termined that it is hypermethylated in CD24+ cells, poten-
tially explaining its lack of expression in these cells
(Figure 4B). This result also suggests that tumor CD24+
and CD44+ cells are epigenetically distinct, a finding con-
firmed by more extended analyses (N.B.-Q., J.Y., S.A.
Mani, M.S., M.H., H. Chen, J.E. Antosiewicz, P.A.,
M.K.H., J.A. Thomson, P. Pharoah, A. Porgador, S.S., R.
Parsons, A.L.R., R.S.G., K.P., unpublished data).
To test the functional relevance of the activation of
TGF-b signaling in cancer CD44+ cells, we investigated
the effect of a dual TGFBR1/TGFBR2 kinase inhibitor
Cancer Cell
Breast Cancer ‘‘Stem Cells’’?Figure 4. TGF-b Pathway in Tumor CD44+ and CD24+ Cells
(A) Semiquantitative RT-PCR analysis of the expression of genes involved in TGF-b signaling in CD24+ and CD44+ cells isolated from pleural effusion
(PE2) and ascites (ASC3). TGFB1 and TGFBR2 are overexpressed in CD44+ cells. GAPDH was used as loading control. Each triangle indicates an
increasing number of PCR cycles (25, 30, 35).
(B) Quantitative methylation-specific PCR (qMSP) analysis of TGFBR2 promoter in CD24+ (white bars) and CD44+ (black bars) cells from primary
cultured pleural effusion (pcPE) or freshly isolated from the indicated invasive ductal carcinoma (IDC) tumor samples.
(C) Semiquantitative RT-PCR analysis of the expression of genes involved in TGF-b signaling and stem-cell function in primary cultured pleural effu-
sion (pcPE) CD24+ and CD44+ cells. TGFBR2, GJA1, and PROCR are only detected in CD44+ cells, while the expression of TGFBR1 and SMAD2 are
the same in the two cell populations. ACTB was used as loading control. Each triangle indicates an increasing number of PCR cycles (25, 30, 35), with
color indicating cells cultured in the absence (white) or presence (black) of TGFBR inhibitor.
(D) Immunoblot analysis of phospho-SMAD2/3 and SMAD2/3 protein levels in primary cultured pleural effusion (pcPE) CD24+ and CD44+ cells in the
presence or absence of TGF-b and the TGFBR inhibitor.
(E) Phase-contrast (PC) images and immunofluorescence analysis of b-catenin, E-cadherin, and ZO-1 expression and cellular localization before and
after treatment with TGFBR inhibitor for primary cultured pleural effusion (pcPE) CD44+ and CD24+ cells. Following treatment with the inhibitor,
CD44+ cells underwent dramatic morphologic changes and redistribution of b-catenin, E-cadherin, and ZO-1 to the cell membrane, while CD24+
cells demonstrated no response.
(F) Cell-cycle profiles of primary cultured pleural effusion (pcPE) CD24+ and CD44+ cells before (black line) and after (red line) treatment with TGFBR
inhibitor. The inhibitor had no effect on the proliferation of either cell type.Cancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc. 265
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Breast Cancer ‘‘Stem Cells’’?(LY2109761) on the growth and differentiation of CD44+
and CD24+ cells cultured in vitro. First, we confirmed
that the expression of TGF-b pathway components and
cell-type-specific genes are the same in primary cultures
as in fresh tumor samples and are not affected by treat-
ment with the TGFBR inhibitor (Figure 4C). We also
confirmed that TGF-b signaling is only activated in
CD44+ cells in response to TGF-b treatment and that
this is inhibited by the TGFBR inhibitor as determined
by the phosphorylation of SMAD2/3 (Figure 4D). CD24+
cells exhibited high basal phopho-SMAD2/3 levels that
could potentially be due to activin signaling or a mutation
in TGFBR1. Next, we analyzed if treatment with the
TGFBR inhibitor affects the phenotypes or proliferation
of CD24+ and CD44+ cells. This treatment resulted in
dramatic morphologic changes in CD44+ cells within
24 hr (Figure 4E). While untreated CD44+ cells were
round-shaped and dispersed, CD44+ cells treated with
the TGFBR inhibitor were more epithelial in appearance
(Figure 4E). To determine if this morphologic change is
the result of epithelial differentiation induced by the inhib-
itor, we analyzed b-catenin, E-cadherin, and ZO-1 by
immunofluorescence (Figure 4E). TGFBR inhibitor treat-
ment led to the localization of all three proteins to the
cell membrane, consistent with the induction of an epithe-
lial cell phenotype. These results prove that the TGF-b
pathway is specifically activated in CD44+ breast cancer
cells and that it regulates, at least in part, their more mes-
enchymal appearance. Consistent with the lack of expres-
sion of TGFBR2 in CD24+ cells (Figure 4C), we did not
detect any changes in these cells following TGFBR inhib-
itor treatment. Interestingly, b-catenin and E-cadherin
were abnormally localized in CD24+ cancer cells, sug-
gesting that, although these cells lack stem-cell markers,
they are not normal differentiated luminal epithelial cells.
The TGFBR inhibitor had no significant effect on the pro-
liferation and survival of CD24+ or CD44+ cells under
the conditions tested (Figure 4F).
Prognostic Value of Gene Signatures Specific for
Either CD44+ and PROCR+ or CD24+ Cancer Cells
To determine the clinical significance of the gene expres-
sion profiles of CD44+, PROCR+, and CD24+ breast can-
cer cells, we investigated whether expression in tumors of
subsets of genes upregulated or downregulated in cancer
CD44+ and PROCR+ cell SAGE libraries compared to
cancer CD24+ cell SAGE libraries are correlated with
breast cancer patient clinical outcome. Two groups of
genes were identified that are statistically significantly as-
sociated with distant metastasis-free survival in three
independent published data sets of patients with lymph-
node-negative tumors who did not receive chemotherapy
or hormonal therapy (Chang et al., 2005; Sotiriou et al.,
2006; van de Vijver et al., 2002; Wang et al., 2005). Two
data sets were used as training sets to select genes likely
to be correlated with outcome, while the third data set was
used only as a test set. Signatures ‘‘A’’ and ‘‘B’’ consist of
genes upregulated and downregulated, respectively, in
cancer CD44+ and PROCR+ cells compared to cancer266 Cancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc.CD24+ cells (Table 2). High expression of signature ‘‘A’’
genes is associated with shorter distant metastasis-free
survival times, while high expression of signature ‘‘B’’
genes is associated with longer distant metastasis-free
survival times (Figures 5A and 5B). In the third data set,
signatures ‘‘A’’ and ‘‘B’’ are also associated with shorter
and longer relapse-free and overall survival times, respec-
tively (Supplemental Data). Neither signature is consis-
tently statistically significantly associated with tumor
estrogen receptor (ER) status or histologic grade, and
each signature does correlate with survival time among
patients with ER+, ER, high-grade, and low-grade tu-
mors (Supplemental Data); therefore, the correlation of
signatures ‘‘A’’ and ‘‘B’’ with outcome is independent of
ER expression and tumor grade.
Since our pathway analysis and TGFBR inhibitor treat-
ment experiment implied that activation of the TGF-bpath-
way in CD44+ breast cancer cells might play an important
role in their invasive phenotype, we also tested whether
expression in tumors of a ‘‘TGF-b cassette’’ correlates
with clinical outcome in the three data sets used above.
The ‘‘TGF-b cassette’’ includes 15 genes more highly
expressed in cancer CD44+ and PROCR+ cells than in
cancer CD24+ cells (Table 1III). High expression of these
genes is statistically significantly associated with shorter
distant metastasis-free survival time in one data set
(Figure 5C), suggesting that activation of the TGF-b path-
way in CD44+ cancer cells may be relevant for disease
progression in a subset of breast cancer patients and
that these patients may benefit from therapy targeting
this pathway.
Localization of CD24+ and CD44+ Cells in Normal
and Tumor Tissue
Since the isolation of the CD24+ and CD44+ cells includes
multiple steps, the possibility that the procedure altered
the expression of some genes cannot be excluded. To
verify the SAGE data by methods using intact tissue and
to determine the number and location of CD24+ and
CD44+ cells in normal breast tissue and breast carcino-
mas, we performed immunohistochemical analyses for
selected genes specific for these two cell populations
based on SAGE (Figure 6A). In normal breast tissue, cells
positive for connexin 43 (Cx43), PROCR, and smooth
muscle actin (SMA) were localized to the basal/myoepi-
thelial layer. Virtually all epithelial (luminal and basal) cells
were positive for CD44, while weak CD24 staining was
detected in some luminal epithelial cells. Interestingly, in
breast tissue of pregnant women, cells positive for
Cx43, CD44, and PROCR were only detected in some
ducts, suggesting a decrease in the expression of these
genes or in the number of cells expressing them.
Next, we analyzed breast tumors of different stages, in-
cluding 20 DCIS (ductal carcinoma in situ) and 250 primary
invasive tumors with different lymph-node and distant-
metastasis status. We observed varying expression of
CD24, CD44, Cx43, CK19, CK17, FN1, and SMA and vary-
ing distribution of cells positive for them (Figure 6B and
data not shown). Some tumors contained only CD44+ or
Cancer Cell
Breast Cancer ‘‘Stem Cells’’?Table 2. Gene Signatures Specific for Either CD44+ and PROCR+ or CD24+ Cancer Cells with Prognostic Value
Matching SAGE tag sequences, counts per 200,000 tags in each indicated SAGE library, and gene symbols and descriptions are
listed for genes in signatures ‘‘A’’ and ‘‘B.’’ These genes are statistically significantly up- and downregulated, respectively, in a pool
of all cancer CD44+ and PROCR+ cell SAGE libraries compared to a pool of all cancer CD24+ cell SAGE libraries. N, normal; PE,
pleural effusion; ASC, ascites; IDC, invasive ductal carcinoma.only CD24+ cells, while others had a mix of the two cell
types or lacked both of them. In some DCIS, we observed
distinct subpopulations of cells mutually exclusively ex-
pressing CD44 and CD24. The expression of CD24 and
CD44 was not statistically significantly correlated with
any of the histopathologic characteristics of the tumors.
To determine if the number of CD44+ or CD24+ cells is
different between primary tumors and distant metastases,
we analyzed matched samples obtained from multiple in-
dependent patients. The frequency of CD24+ cells was
dramatically higher in distant metastases regardless of
their sites (all from solid organs such as liver, lung, bone,
and adrenal gland) compared to primary tumors in all eight
patients analyzed, while the numbers of cells positive forCCx43, CD44, SMA, CK19, and CK17 did not show consis-
tent differences (Figure 6C and data not shown).
DISCUSSION
The hypothesis that tumors contain a subpopulation of
cells with stem-cell characteristics has generated re-
newed interest and excitement in part due to the assump-
tion that ineffective targeting of this cell population is re-
sponsible for therapeutic failures and recurrences (Dean
et al., 2005; Eckfeldt et al., 2005). Unfortunately, there is
very limited data available on the molecular identity and
clinical relevance of breast ‘‘cancer stem cells.’’ Analysis
of the number of putative breast cancer stem cellsancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc. 267
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Breast Cancer ‘‘Stem Cells’’?Figure 5. Clinical Relevance of Gene Expression Differences between CD24+, CD44+, and PROCR+ Breast Cancer Cells
(A) Tumor gene expression levels and distant metastasis-free survival for patients with and without signature ‘‘A,’’ which consists of genes upregulated in
pooled cancer CD44+ and PROCR+ cell SAGE libraries versus pooled cancer CD24+ cell SAGE libraries. In each heat map, rows represent microarray
probes corresponding to the genes in signature ‘‘A,’’ and columns represent tumors from data sets 1 (Wang et al., 2005), 2 (Sotiriou et al., 2006), and 3
(Chang et al., 2005; van de Vijveret al., 2002) ordered by averageexpression value for the signature. Patients with tumors with average expression values
at or above the 75th percentile were called ‘‘signature A+’’; all others were called ‘‘signature A.’’ Bottom bars indicate presence (blue) or absence
(black) of distant metastases in the patients from which the tumors were obtained. Kaplan-Meier curves and log-rank test p values show that ‘‘signature
A+’’ patients in all three data sets have statistically significantly (p < 0.05) shorter distant metastasis-free survival times than ‘‘signature A’’ patients.
(B) Tumor gene expression levels and distant metastasis-free survival for patients with and without signature ‘‘B,’’ which consists of genes upregu-
lated in pooled cancer CD24+ cell SAGE libraries versus pooled cancer CD44+ and PROCR+ cell SAGE libraries. Rows and columns of heat maps
are as described above, except that probes correspond to the genes in signature ‘‘B.’’ Patients with tumors with average expression values at or
below the 25th percentile were called ‘‘signature B’’; all others were called ‘‘signature B+.’’ Bottom bars are as described above. Kaplan-Meier
curves and log-rank test p values show that ‘‘signature B’’ patients in all three data sets have statistically significantly (p < 0.05) shorter distant
metastasis-free survival times than ‘‘signature B+’’ patients.268 Cancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc.
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Breast Cancer ‘‘Stem Cells’’?Figure 6. Immunohistochemical Analyses of Normal Breast Tissue and Breast Carcinomas
(A) Examples of immunohistochemical analyses of normal and pregnant breast tissue using the indicated genes. All CD44+ cell markers (Cx43, CD44,
PROCR, and SMA) are positive in basal cells, and SMA is also positive in terminally differentiated myoepithelial cells. In pregnant breast tissue, cells
positive for Cx43, CD44, and PROCR are only localized in terminal ducts. Scale bars, 100 mM.
(B) Representative examples of immunohistochemical staining patterns observed in DCIS (ductal carcinoma in situ) and invasive ductal breast
carcinomas using antibodies against the indicated genes. Cx43, CD44, CD24, and SMA have varying expression and distribution in epithelial cells.
SMA is also positive in DCIS myoepithelial cells and myofibroblasts. Scale bars, 200 mM.
(C) Immunohistochemical analyses of a primary breast tumor and matched distant metastases from the indicated organs for the expression of CD44,
CD24, and SMA. The primary tumor was CD24 negative, but all distant metastases were strongly CD24 positive. Scale bars, 200 mM.identified by immunohistochemistry as CD44+/CD24
cells failed to identify statistically significant association
between the frequency of these cells and clinical behavior,
although tumors that developed distant metastases
(mainly in the bone) had a higher fraction of CD44+/
CD24 cells (Abraham et al., 2005). Investigation of the
prognostic significance of an 11-gene, BMI1-driven stem
cell gene signature in a large collection of gene expression
data from several different tumor types determined that
this signature is a powerful predictor of short disease-
free and overall survival and the risk of distant metastases
(Glinsky et al., 2005).
To better understand the molecular differences be-
tween CD24+ and CD44+ cells in breast carcinomas as
well as analogous cells from normal breast tissue, we
determined their comprehensive gene expression and
genetic profiles. Using this approach, we made several
important conclusions. First, the gene expression profileCof CD44+ cells resembles that of stem cells, and normal
and tumor CD44+ cells are more similar to each other
than to CD24+ cells from the same tissue. Second, tumor
CD44+ and CD24+ cells are clonally related but not al-
ways identical since in some tumors CD24+ cells have ad-
ditional genetic alterations besides the ones shared with
CD44+ cells. Third, the distinct gene expression profiles
of the cells reflect the activation of distinct signaling path-
ways, and some of these are specific for breast cancer
CD44+ cells, suggesting approaches for their therapeutic
targeting. Interestingly, genes involved in cell motility and
angiogenesis were highly expressed in CD44+ cells, while
genes involved in RNA splicing and carbohydrate metab-
olism were highly expressed in CD24+ cells. This is con-
sistent with CD44+ cells demonstrating a more mesen-
chymal, motile, and less proliferative stem-cell-like
profile. Fourth, CD44+ breast cancer cells are negative
for ER even in some ER+ tumors (where ER is expressed(C) Tumor gene expression levels and distant metastasis-free survival for patients with high and low expression of a CD44+ cell-specific ‘‘TGF-b cas-
sette,’’ which consists of the genes in Table 1III. Rows of the heat map represent microarray probes corresponding to genes in the ‘‘TGF-b cassette,’’
and columns represent tumors from data set 1 ordered by average expression value for the cassette. Patients with tumors with average expression
values at or above the 75th percentile were called ‘‘TGF-b cassette high’’; all others were called ‘‘TGF-b cassette low.’’ Bottom bars are as described
above. Kaplan-Meier curves and a log-rank test p value show that ‘‘TGF-b cassette high’’ patients have statistically significantly (p < 0.05) shorter
distant metastasis-free survival times than ‘‘TGF-b cassette low’’ patients.ancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc. 269
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Breast Cancer ‘‘Stem Cells’’?in CD24+ cells). Fifth, breast cancer CD44+ and CD24+
cell gene expression signatures correlate with clinical out-
come. Since these signatures were generated using ex-
pression data for bulk tumors, this result could mean
that the numbers of cancer CD44+ and CD24+ cells within
tumors are associated with clinical outcome. Specifically,
tumors composed of mostly CD44+ cells may have worse
clinical behavior than tumors mainly composed of CD24+
cells. Many genes in signature ‘‘A’’ (characteristic of
breast cancer CD44+ cells) are involved in cell motility, in-
vasion, apoptosis, and ECM remodeling, while signature
‘‘B’’ (characteristic of breast cancer CD24+ cells) contains
several genes involved in inflammation and immune
function.
One of the pathways we found specifically activated
in CD44+ breast cancer cells is the TGF-b signaling
pathway, known to play an important role in human
embryonic stem cells as well as in tumorigenesis (James
et al., 2005; Moses and Serra, 1996; Muraoka-Cook
et al., 2005; Roberts and Wakefield, 2003; Siegel and
Massague, 2003). TGF-b plays a dual role in tumor pro-
gression: it is one of the most potent inhibitors of cell
proliferation, but it promotes invasion, angiogenesis, epi-
thelial-mesenchymal transition (EMT), and metastasis
(Bates and Mercurio, 2005; Roberts and Wakefield,
2003). Our results suggest that cells with different pheno-
types, even within the same tumor and tissue type, re-
spond differently to TGF-b activation. Intriguingly, we
found that, in the tumors analyzed, the specific activation
of TGF-b signaling in CD44+ breast cancer cells is due to
the restricted expression of the TGFBR2 receptor in these
cells and its epigenetic silencing in CD24+ cells. Correlat-
ing with this, treatment with a TGFBR kinase inhibitor
specifically affected CD44+ tumor cells, leading to a mes-
enchymal-to-epithelial transition. Further emphasizing the
importance of TGF-b signaling in CD44+ breast cancer
cells, high expression of TGF-b pathway genes was asso-
ciated with shorter distant metastasis-free survival in a set
of breast cancer patients. These findings may have imme-
diate therapeutic implications due to the current testing of
TGF-b pathway inhibitors in clinical trials (Arteaga, 2006).
Our comprehensive gene expression profiling was lim-
ited to a few cases, so we analyzed the expression of se-
lected genes by immunohistochemistry in a larger set of
normal breast tissue and breast carcinomas of different
stages. This demonstrated that cells expressing CD44+
cell-specific genes (CD44, Cx43, and PROCR) are local-
ized to the basal cell layer of ducts and alveoli in normal
breast tissue and that their number may dramatically de-
crease in late pregnancy. Pregnancy is thought to lead
to the terminal differentiation of breast epithelial stem
cells, and early full-term pregnancy reduces the risk of
certain breast cancer (postmenopausal ER+ tumors), po-
tentially by reducing the number of cells that could be
targets of cellular transformation (Polyak, 2006; Russo
et al., 2005; Schedin, 2006). Our results are consistent
with this hypothesis, although proving it would require
the analysis of normal breast tissue from women with
differing parity and breast cancer history.270 Cancer Cell 11, 259–273, March 2007 ª2007 Elsevier Inc.The immunohistochemical analysis of tumors revealed
high heterogeneity for the expression of selected genes
among samples. The expression of CD24 and CD44 (ana-
lyzed alone or in combination) in primary invasive breast
carcinomas was not correlated with any tumor character-
istics. The expression of SMA (in tumor cells) in primary
tumors correlated with lymph node, distant metastasis,
ER, and HER2 status, while Cx43 expression was associ-
ated with ER status. Surprisingly, we found that the num-
ber of CD24+ cells was dramatically and consistently
increased in distant metastases irrespective of the type
of the primary tumor and location of the distant metasta-
sis. Although this observation seemingly contradicts the
hypothesis that CD24+ cells represent more differentiated
and less tumorigenic cancer cells, it is consistent with re-
ports associating CD24 expression with tumor progres-
sion and metastatic behavior (Baumann et al., 2005;
Bircan et al., 2006; Kristiansen et al., 2003). There are sev-
eral possible explanations for this apparent paradox. The
expression of one gene may not be sufficient to uniquely
identify a cell with a particular phenotype. Tumorigenicity
studies in experimental systems (e.g., injection of tumor
cells into mammary fat pads of immunodeficient mice)
may not reflect the behavior of the cells in patients. Tumor
cells may change their phenotypes and gene expression
profiles during the metastatic process. Finally, as also
suggested by our FISH result demonstrating clonal ge-
netic differences between CD24+ and CD44+ cells within
a tumor, CD44+ and CD24+ cells may undergo indepen-
dent clonal evolution.
In summary, our comprehensive molecular and pheno-
typic analysis of CD24+ and CD44+ cells from breast
carcinomas revealed that they represent defined cell pop-
ulations with distinct gene expression, epigenetic, and
genetic profiles. Although CD44+ cells appear to express
many stem-cell markers, the genetic difference between
CD24+ and CD44+ cells within a tumor questions the
validity of the cancer-stem-cell hypothesis in breast can-
cer and suggests clonal evolution involving intratumoral
heterogeneity as an alternative explanation of our data
and previously published data. Importantly, gene signa-
tures associated with CD24+ and CD44+ tumor cells
may have clinical relevance, and signaling pathways spe-
cifically activated in CD44+ cells could be used for their
therapeutic targeting. Further studies, especially clinical
trials, are necessary to validate our findings and to deter-
mine if targeting CD44+ tumor cells will have an impact on
the clinical management of breast cancer patients.
EXPERIMENTAL PROCEDURES
Clinical Samples
Fresh, frozen, or formalin-fixed, paraffin-embedded tumor specimens
were collected at Harvard-affiliated hospitals (Boston, MA) and Johns
Hopkins University (Baltimore, MD). All human tissue was collected
using protocols approved by the Institutional Review Boards; informed
consent was obtained from each individual who provided tissues with
linked clinical data. Fresh tissue samples were immediately processed
for immunomagnetic purification as described in detail in the Supple-
mental Data. Tissue microarrays were purchased from Imgenex (CA),
Cancer Cell
Breast Cancer ‘‘Stem Cells’’?obtained from Cooperative Breast Cancer Tissue Resource, or gener-
ated at Johns Hopkins University.
RT-PCR, SAGE, SNP Array, and qMSP Analysis
RT-PCR and SAGE analyses were performed essentially as previously
described (Allinen et al., 2004). Clustering of SAGE libraries was per-
formed using Cluster (Eisen et al., 1998) and the tags listed in Table
S7, and results were visualized with MapleTree (developed by
L. Simirenko). SNP array analysis was performed using Affymetrix
250K arrays, and data were analyzed using published protocols
(LaFramboise et al., 2005). TGFBR2 promoter methylation analysis
was performed as described previously (Hu et al., 2005) using pub-
lished primers (Zhang et al., 2004; Zhao et al., 2005).
Fluorescence In Situ Hybridization
BAC probes RP11-157A11 (1q21.3), RP11-812I22 (17q21.2), and
RP11-661N22 (6q21-q23.2) were labeled with digoxigenin (Roche,
Indianapolis, IN) using an enzyme mix from the BioNick labeling kit
(Invitrogen, Carlsbad, CA) as done previously (Zhao et al., 1995).
RP11-167M14 (17q21.3-q22.1), CTD-2349A18 (8q24), RP11-606C3
(7p21.1), and RP11-697I2 (17q11-q12) were labeled with biotin using
the same kit. CD24+, CD44+, and PROCR+ cultures were treated
with colcemid, harvested, and used for metaphase chromosome
spreads preparations according to standard protocols. Hybridization
of metaphase chromosomes was performed as previously described
(Ney et al., 1993). The probes were detected using reagents supplied
by Cytocell Technologies, Ltd. according to the manufacturer’s rec-
ommendation. Images were captured using the CytoVysion Imaging
System (Applied Imaging, Pittsburgh, PA).
Functional Annotation, Network Analysis, and Correlation
of Gene Expression with Outcome
Genes highly represented in the SAGE libraries were functionally
classified by gene ontology biological processes using the DAVID
Functional Annotation Tool (http://david.abcc.ncifcrf.gov/summary.
jsp). For network analyses, sets of genes differentially expressed
between CD44+ and CD24+ cells were uploaded into the MetaCore
analytical suite version 2.0 (GeneGo, Inc., St. Joseph, MI), and analysis
was conducted as described previously (Nikolsky et al., 2005a; Nikol-
sky et al., 2005b). Gene signatures that correlated with outcome were
identified using Cox proportional hazards regression, hierarchical clus-
tering, Kaplan-Meier analysis, and log-rank tests. TGF-b genes were
tested for correlation with clinical outcome using Kaplan-Meier analy-
sis and log-rank tests. Detailed descriptions of these methods are in-
cluded in the Supplemental Data.
Primary Cell Culture, FACS, and Immunoblot Analyses
Purified cells were cultured using protocols described in detail in the
Supplemental Data. FACS analysis was performed as described be-
fore (Polyak et al., 1994) using FITC- or PE-conjugated CD24, CD44,
and PROCR antibodies from BD Biosciences (San Jose, CA). Immuno-
cytochemistry and immunoblot analyses were performed using BCTN,
phospho-SMAD2/3, and SMAD2/3 antibodies from Cell Signaling
(Beverly, MA), CDH1 from BD Biosciences (San Jose, CA), and ZO1
from Chemicon (Temecula, CA) and protocols recommended by the
provider. Cells were treated with the LY2109761 TGFBR inhibitor
(Eli Lilly, IN) at 0.5 mM final concentration for 24 hr prior to analysis.
Cell-cycle analysis was performed essentially as described (Polyak
et al., 1994).
Immunohistochemistry
Immunohistochemistry was performed essentially as described earlier
(Porter et al., 2003) using the following primary antibodies: CD24 and
CD44 (LabVision, Fremont CA), Cx43 (Cell Signaling, Beverly, MA),
PROCR (BD Biosciences, San Jose, CA), and SMA, CK17, and CK19
(DAKO, Carpinteria, CA). Antibody staining was scored by pathologist
P.A. on a scale of 0–3 for intensity (0 = no staining, 1 = faint signal, 2 =
moderate, and 3 = intense staining) and 0–3 for extent (0 = no, 1 < 30%,C2 = 30%–70%, and 3 > 70% positive cells). For statistical analyses,
a cumulative score at or above 2 was considered positive.
Supplemental Data
The Supplemental Data include 15 supplemental figures, seven sup-
plemental tables, and Supplemental Experimental Procedures and
can be found with this article online at http://www.cancercell.org/
cgi/content/full/11/3/259/DC1/.
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